Studies on Sepsis and severe infections

1 September, 2023

PRECISION

2024-01-03T18:05:48+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial Brief Description The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The PRECISION is a proof-of-concept, phase II randomized clinical

15 February, 2023

MODIFY

2024-01-03T17:02:26+03:00By |Categories: Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial) Brief Description The aim of the study is to demonstrate if using a combined strategy of rapid molecular diagnosis with BioFire® FilmArray® Blood Culture Identification 2 Panel and

1 February, 2023

HDM-FUN-Candidemia

2024-01-03T16:56:31+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia: The HDM-FUN-Candidemia trial Brief Description Invasive fungal infections are an important cause of morbidity and mortality and lead to numerous hospital and ICU admissions. Candidemia is associated with a suppressed immune status

10 January, 2023

SAVE-LONG

2023-05-22T14:50:00+03:00By |Categories: Non-Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Symptom-guided Anakinra treatment for the Validation of immunE dysfunction persisting for LONG after hospital discharge for COVID-19 (SAVE-LONG) Brief Description SAVE-LONG is a call to the development of diagnostic tools and therapeutic modalities for patients with Long-COVID Syndrome. Details Status: ongoing Study Type: Non-interventional Study phase: II &

10 October, 2022

INSPIRE

2024-04-02T11:19:09+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: , |

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard

1 April, 2022

H4COVID

2023-01-09T12:10:52+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Hydrogen Sulfate guided therapy with STS for COVID-19 patients in need of Critical Care: The H4COVID open-label, randomized, triple-arm trial Brief Description H4COVID open-label study is aiming to describe the safety of administration of three doses of STS to critically ill patients with confirmed COVID-19. Details Status: Recruiting

1 April, 2022

BEYOND

2024-02-07T15:52:23+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: |

Completed study Official Study Title Bezlotoxumab Υielded Οutcomes by addressing personalized Needs in Clostridioides Difficile infection: the BEYOND double-blind randomized clinical trial Brief Description Previous data from our group have shown that integrated information from SNPs of the host DNA, IL-8 and the enrichment of the stool microbiome can indicate the patients with infection

1 July, 2021

ImmunoSep

2024-02-07T15:54:02+03:00By |Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: |

Ongoing study Official Study Title Personalized Immunotherapy in Sepsis: a multicentre and multinational, double-blind, double-dummy randomized clinical trial Brief Description Previous findings coming from the randomized clinical trial PROVIDE have showed that serum ferritin and expression of HLA-DR on circulating monocytes are reliable diagnostic markers of macrophage activation syndrome and of sepsis-induced immunoparalysis. The

1 May, 2021

Differential response induced by LPS and MPLA in immunocompetent and septic individuals

2023-02-16T13:25:47+03:00By |Categories: Publications, Sepsis and severe infections|Tags: , |

Chloé Albert Vega, Eleni Karakike, François Bartolo, William Mouton, Elisabeth Cerrato, Karen Brengel-Pesce, Evangelos J. Giamarellos-Bourboulis, François Mallet, Sophie Trouillet-Assant Clinical Immunology 2021 May;226:108714 DOI: 10.1016/j.clim.2021.108714 View article 🡇 Funding This work was supported by Marie Sklodowska-Curie Innovative Training H2020-MSCA-ITN-2015, under the grant agreement No 676129. Keywords: Immune functional

23 April, 2021

FERMIN

2023-01-15T21:59:11+03:00By |Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: |

Completed study Official Study Title FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) Brief Description FERMIN is a randomized clinical trial aiming to assess the clinical impact of fenofibrate to improve clinical outcomes in patients with COVID-19. Details Status: Completed Study Type: Interventional (Clinical Trial)

Go to Top